BeStock  
Stocks › Biotechnology › TLX

Telix Pharmaceuticals TLX

US equityMarket cap rank #2480Biotechnology
$8.37 −$0.34 (-3.90%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.37 0.00%
Open$8.66
Prev close$8.71
Day range$8.37 – $8.70
Volume269.4K
Market cap$2.84B
P/E (TTM)86.3
Dividend yield–

Fundamentals

Latest reported quarter: ANNUAL, ended Dec 2025

Revenue$803.79M+55.6% YoY
Operating profit$18.05M-67.5% YoY
Net profit-$7.13M-121.2% YoY
Diluted EPS-$0.02-121.6% YoY
Free cash flow-$15.08M-1,487.3% YoY

Free cash flow by quarter

$-25.2MMar '22$-22.4MJun '22$-3.5MSep '22$1.1MDec '22$1.6MMar '23$7.2MJun '23$13.7MSep '23$-15.1MDec '23

Annual revenue

$3.6MFY20$3.6MFY21$108.9MFY22$333.0MFY23$516.6MFY24$803.8MFY25

Profitability & balance sheet

Gross margin53.7%
Operating margin5.3%
Net margin3.8%
Return on equity7.4%
Return on assets2.6%
Return on invested capital6.4%
Current ratio2.01
Liabilities / assets64.2%
Cash & investments$251.91M
Total debt$575.95M
Net cash (debt)-$324.04M

Where the revenue comes from

Quarter 2025/FY

By business line

  • Precision Medicine$621.93M 71.0%
  • Manufacturing Solutions$245.11M 28.0%
  • Therapeutics$9.27M 1.1%

By region

  • United States$784.91M 97.7%
  • China$9.83M 1.2%
  • Other countries$9.06M 1.1%

Balance sheet

Line item 2026 Q2 2025 ANNUAL 2025 Q4 2025 Q2 2024 ANNUAL
Total Assets $1.36B $1.16B $1.16B $1.19B $940.38M
Total Current Assets $488.02M $330.28M $330.28M $398.01M $570.12M
Cash and Cash Equivalents & Short-Term Investments $251.91M $141.87M $141.87M $207.16M $440.00M
-Cash and Cash Equivalents $251.91M $141.87M $141.87M $207.16M $440.00M
Receivables $170.39M $138.37M $138.37M $129.52M $99.65M
-Accounts Receivable $163.56M $129.20M $129.20M $123.63M $86.93M
-Taxes Receivable $6.83M $7.88M $7.88M $5.89M $10.96M
Inventory $39.03M $37.08M $37.08M $35.23M $23.62M
Other Current Assets $26.69M – – $26.10M –
Total Non-Current Assets $873.83M $833.71M $833.71M $791.94M $370.26M
Net PPE $129.63M $115.61M $115.61M $74.18M $33.65M
-Gross PPE $129.63M $133.53M $133.53M $85.11M $40.53M
Investments and Advances $40.41M $3.68M $3.68M $4.06M $3.77M
-Available for Sale Securities $40.41M – – – –
Goodwill and Other Intangible Assets $584.61M $592.82M $592.82M $584.17M $257.86M
-Goodwill $197.51M $198.99M $198.99M $185.81M $66.59M
-Other Intangible Assets $387.10M $393.84M $393.84M $398.36M $191.27M
Non-Current Deferred Assets $85.30M $59.35M $59.35M $75.77M $28.92M
Other Non-Current Assets $33.89M $60.90M $60.90M $53.76M $46.06M
Total Liabilities $874.18M $748.61M $748.61M $768.01M $587.44M
Total Current Liabilities $242.34M $231.62M $231.62M $298.58M $205.09M
Payables $202.82M $137.42M $137.42M $141.60M $83.83M
-Total Tax Payable $33.85M $30.74M $30.74M $51.74M $30.09M
-Other Payable $168.97M $17.86M $17.86M $38.17M $4.06M
Short-Term Debt and Capital Lease Obligation $15.42M $18.66M $18.66M $21.06M $13.31M
-Current Debt $11.51M $13.11M $13.11M $12.69M $11.76M
-Current Capital Lease Obligation $3.92M $5.55M $5.55M $8.37M $1.55M
Current Provisions $520,000.00 $562,000.00 $562,000.00 $896,000.00 $576,000.00
Current Deferred Liabilities $390,000.00 $11.47M $11.47M $4.40M $6.97M
Other Current Liabilities $2.90M $11.54M $11.54M $72.28M $53.22M
Total Non-Current Liabilities $631.83M $516.99M $516.99M $469.43M $382.35M
Long Term Debt and Capital Lease Obligation $564.44M $448.45M $448.45M $397.19M $346.85M
-Long Term Debt $504.88M $391.91M $391.91M $371.48M $341.81M
-Long Term Capital Lease Obligation $59.56M $56.53M $56.53M $25.71M $5.04M
Non-Current Liabilities $8.56M $9.18M $9.18M $9.33M $8.53M
Non-Current Deferred Liabilities $43.30M $44.71M $44.71M $40.21M $7.83M
Employee Benefits $607,000.00 $444,000.00 $444,000.00 $356,000.00 $305,000.00
Other Non-Current Liabilities $14.93M $14.21M $14.21M $22.35M $18.83M
Total Equity $487.68M $415.38M $415.38M $421.94M $352.94M
Stockholders' Equity $487.68M $415.38M $415.38M $421.94M $352.94M
Capital Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $490.92M $479.96M $479.96M $473.11M $414.01M
Retained Earnings -$110.90M -$154.54M -$154.54M -$150.98M -$152.91M
Gains/Losses Not Affecting Retained Earnings -$13.24M $89.95M $89.95M $99.81M $91.84M
Other Equity Interests $120.89M – – – –
-Other Receivables – $1.29M $1.29M – $1.77M
Prepaid Assets – $12.96M $12.96M – $6.84M
-Accumulated Depreciation – -$17.92M -$17.92M -$10.94M -$6.88M
-Long Term Equity Investment – $3.68M $3.68M $4.06M $3.77M
Non Current Accounts Receivables – $1.34M $1.34M – –
-Accounts Payable – $88.81M $88.81M $51.69M $49.68M
Current Accrued Expenses – $32.61M $32.61M $43.71M $33.05M

Income statement

Line item 2025 ANNUAL 2024 ANNUAL 2023 ANNUAL 2022 ANNUAL 2021 ANNUAL
Total Revenue as Reported $803.79M $516.55M $332.98M $108.91M –
Total Operating Revenue $803.79M $516.55M $332.98M $108.91M $3.55M
Cost of Revenue $377.36M $180.39M $123.45M $44.34M $1.85M
Gross Profit $426.44M $336.16M $209.53M $64.58M $1.70M
Operating Expense $408.39M $280.58M $174.57M $115.05M $73.32M
Selling and Admin Expenses $237.15M $152.19M $89.38M $59.47M $29.58M
-Selling & Marketing Expense $141.36M $72.62M $39.72M $29.24M $4.27M
-General & Admin Expense $95.79M $79.57M $49.67M $30.23M $25.31M
Research & Development $171.25M $127.93M $85.32M $54.89M $24.74M
Other Operating Expenses -$12,000.00 $458,000.00 -$130,000.00 $691,864.97 $15.25M
Operating Profit $18.05M $55.58M $34.97M -$50.48M -$71.62M
Net Non-Operating Interest Income (Expense) -$35.04M -$17.26M -$8.41M -$4.55M -$3.78M
Non-Operating Interest Income $5.83M $7.18M $671,000.00 $680.30 –
Non-Operating Interest Expense $40.42M $24.15M $8.94M $4.50M $3.78M
Total Other Finance Costs $452,000.00 $292,000.00 $142,000.00 $56,464.89 –
Other Income (Expense) $11.72M -$407,000.00 -$23.96M -$12.06M $17.07M
Gain on Sale of Security -$563,000.00 $11.90M -$734,000.00 -$760,575.26 $1.23M
Special Income (Charges) $11.05M -$12.60M -$23.24M -$11.37M –
-Less:Restructuring and Mergern & Acquisition -$11.62M $13.08M $22.69M $11.37M –
-Less:Impairment of Capital Assets $566,000.00 -$475,000.00 $550,000.00 $0.00 –
Other Non-Operating Income (Expenses) $1.23M $299,000.00 $14,000.00 $61,907.29 $15.84M
Pretax Profit -$5.27M $37.92M $2.59M -$67.09M -$58.33M
Tax $1.86M $4.23M -$1.61M $3.71M $32,620.99
Net Profit -$7.13M $33.69M $4.21M -$70.80M -$58.36M
Profit from Continuing Operations -$7.13M $33.69M $4.21M -$70.80M -$58.36M
Net Income to Parent Company -$7.13M $33.69M $4.21M -$70.80M -$58.36M
Net Income to Common Stockholders -$7.13M $33.69M $4.21M -$70.80M -$58.36M
Basic EPS -$0.02 $0.10 $0.01 -$0.23 -$0.21
Diluted EPS -$0.02 $0.10 $0.01 -$0.23 -$0.21
Depreciation & Amortization & Depletion – – – – $3.75M
-Depreciation & Amortization – – – – $3.75M

Cash flow

Line item 2025 ANNUAL 2024 ANNUAL 2023 ANNUAL 2023 Q4 2023 Q3
Net cash flow from investing -$285.92M -$86.69M -$16.84M -$1.30M -$13.61M
Net Cash Flow from Continuing Investing Activities -$285.92M -$86.69M -$16.84M -$1.30M -$13.61M
Net PPE Purchase and Sale -$25.69M -$9.12M -$6.31M – –
Net Intangibles Purchase and Sale -$18.08M -$13.07M -$802,000.00 – –
Net Business Purchase and Sale -$229.03M -$23.20M -$995,000.00 – –
Net Investment Purchase and Sale -$892,000.00 -$32.91M -$8.70M – –
Net Other Investing Changes -$12.22M -$8.40M -$37,000.00 $15.51M -$13.61M
Financing Cash Flow -$3.72M $416.79M $7.09M $1.85M $2.21M
Net Cash Flow from Continuing Financing Activities -$3.72M $416.79M $7.09M $1.85M $2.21M
Net Issuance Payments Of Debt -$5.53M $425.84M $2.92M $1.15M $172,216.58
Net Common Stock Issuance $1.81M $662,000.00 $4.17M $5,599.88 $2.27M
Ending Cash Balance $141.87M $440.00M $84.30M $84.30M $88.32M
Net Change in Cash -$306.93M $357.59M $4.53M -$7.42M $2.33M
Beginning Cash Balance $440.00M $84.30M $78.78M $88.32M $84.65M
Effect of Exchange Rate Changes $8.80M -$1.89M $992,000.00 -$631,848.14 $1.34M
Free Cash Flow -$61.07M $5.31M $7.16M -$15.08M $13.73M
Net Other Financing Charges – -$9.71M – – -$233,263.50

Discussion

No comments yet — be the first to weigh in on TLX.

Sign in to join the discussion.

Scroll to Top